Key result
Sex influences medical treatment and outcomes in chronic heart failure, with evidence suggesting a potential female survival benefit despite women being underrepresented in clinical trials.
Why the study?
Does sex influence the treatment effects and survival outcomes of guideline-recommended therapies in patients with chronic heart failure?
Does sex influence the treatment effects and survival outcomes of guideline-recommended therapies in patients with chronic heart failure?
This review highlights the need for sex-specific analyses in heart failure trials, given evidence of sex-specific effects of guideline-recommended drugs and the underrepresentation of women in clinical research.
Answers are grounded in this paper and cite their sources.
Requires sex-specific HF drug considerations in guidelines; extends evidence by addressing female underrepresentation in trials.
The population is aging, the prevalence of heart failure increases with age, and on average women live longer than men. There is evidence for sex-specific effects of individual, guideline-recommended drugs used for treatment of chronic heart failure. Women are underrepresented in most clinical trials and only a minority of drug applications to regulatory authorities have included sex analyses. The present review focuses on the potential female survival benefit in heart failure, the influence of sex on medical treatment in a broader sense, and the potential benefit to be derived from guideline recommended treatment and common adjunctive heart failure medication.
No takes yet. Share an insight, caveat, or question.
Frankenstein et al. (2011) conducted a review in Chronic Heart Failure. Sex was evaluated. Sex influences medical treatment and outcomes in chronic heart failure, with evidence suggesting a potential female survival benefit despite women being underrepresented in clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: